News & Views | Published:

CROSS-PRESENTATION

Translate less, prime better, to improve anti-tumor responses

The N6-methyladenosine (m6A) RNA-modification pathway affects numerous aspects of immune responses. A new study now demonstrates that m6A modification of transcripts encoding lysosomal proteases limits the efficiency of tumor-antigen cross-presentation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Han, D. et al. Nature 566, 270–274 (2019).

  2. 2.

    Meyer, K. D. & Jaffrey, S. R. Annu. Rev. Cell Dev. Biol. 33, 319–342 (2017).

  3. 3.

    Li, H.-B. et al. Nature 548, 338–342 (2017).

  4. 4.

    Winkler, R. et al. Nat. Immunol. 20, 173–182 (2019).

  5. 5.

    Shi, H. et al. Nature 563, 249–253 (2018).

  6. 6.

    Theisen, D. J. et al. Science 362, 694–699 (2018).

  7. 7.

    Theisen, D. J. et al. Cancer Immunol. Res. 7, 29–39 (2019).

  8. 8.

    Alloatti, A. et al. J. Exp. Med. 214, 2231–2241 (2017).

  9. 9.

    Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Nat. Rev. Immunol. 12, 557–569 (2012).

  10. 10.

    Gros, M. & Amigorena, S. Front. Immunol. 10, 41 (2019).

  11. 11.

    Samie, M. & Cresswell, P. Nat. Immunol. 16, 729–736 (2015).

  12. 12.

    Kreiter, S. et al. Nature 520, 692–696 (2015).

Download references

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Sebastian Amigorena.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Regulation of antigen cross-presentation by YTHDF1.